Meeting
2023 ASCO Quality Care Symposium
CHIPping in: Clonal hematopoiesis clinics in community oncology.
Authors
Michael Byrne
Tennessee Oncology, Nashville, TN
Michael Byrne, Ashley Wyse, Nick Barkemeyer, Jonathan Abbas, Larry Edward Bilbrey, David Alan Slosky, Natalie R. Dickson, Stephen Matthew Schleicher, Neha M. Jain, Thomas Stricker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Late- and Long-Term Effects/Comorbidities
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 499)
DOI
10.1200/OP.2023.19.11_suppl.499
Abstract #
499
Poster Bd #
L25
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
First Author: Catherine Handy Marshall
Poster
2021 ASCO Annual Meeting
Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA).
First Author: Emmanuel S. Antonarakis
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie